B-Cell Non-Hodgkin Lymphomas(NHL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Conditions
Keywords
CLL, SLL, NHL, SHC014748M, Phosphatidylinositol 3-kinase (PI3K)
Brief summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of SHC014748M in patients with relapsed or refractory indolent B-cell hematologic malignancies.
Detailed description
This is a phase I, sequential dose escalation followed by cohort expansion study of SHC014748M, an oral inhibitor of PI3K delta, in patients with relapsed or refractory indolent B-cell hematologic malignancies.
Interventions
DRUGSHC014748M
a selective PI3Kδ inhibitor
Sponsors
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1.18- 75 years of age. 2.Histologically or cytologically confirmed diagnosis of relapsed or refractory indolent B-cell hematologic malignancies, including but not limited to CLL / SLL, FL (grade 1, 2 or 3a), or MZL. 3.Patients have received at least 1 prior regimen (at least 2 cycles). 4.Eastern Cooperative Oncology Group (ECOG) performance score of 0-2. 5.Life expectancy ≥ 3 months. 6.Patients have at least 1 measurable lesion that measures ≥1.5 cm in a single dimension as assessed by CT or MRI. 7.Adequate organ function, as defined by the following values: ANC≥1.0×10\^9/L； PLT≥50×10\^9/L； Hb≥80 g/L； TBIL≤1.5×ULN； ALT and AST≤2.5×ULN； BUN and Cr≤1.5×ULN； LVEF≥50%； QTcF \<450 ms for male, QTcF \<470 ms for female； 8.Men and women of childbearing potential are willing to employ an effective method of contraception for the entire duration of study and 6 months after the last dose, and female subjects of childbearing potential have a negative pregnancy test at baseline. 9.Subjects did not participate in other clinical trials within 3 months prior to study entry.
Exclusion criteria
1. Disease progression after previous treatment with any PI3Kδ inhibitors. 2. Had any other anti-tumor treatment within 4 weeks prior to screening (including radiotherapy, chemotherapy, hormone therapy, surgery or targeted therapy). 3. Evidence of central nervous system involvement of the malignancy. 4. Evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, uncontrolled pleural effusion and ascites, uncontrolled diabetes, non-infectious pneumonia, and any other severe cardiovascular, respiratory, nervous and mental diseases. 5. Any of the severe heart diseases, including New York Heart Association (NYHA) Class II or greater heart failure, arrhythmias requiring medical treatment, and history of myocardial infarction or unstable angina within 6 months prior to screening. 6. Require any concomitant medication known to prolong the QT interval during the study. 7. Evidence of active bacterial, fungal, or viral infection. 8. Active infection with hepatitis B virus (HBV) (HBsAg positive, or HBsAg negative and HBV-DNA positive), hepatitis C virus (HCV), or human immunodeficiency virus (HIV). 9. Use of high-dose glucocorticoids (eg, ≥20 mg/day prednisone) or other immunosuppressants within 4 weeks prior to study entry. 10. Concomitant use of any strong inhibitors or inducers of CYP3A4. 11. Use of G-CSF or blood transfusion within 7 days before the hematology test at screening. 12. Prior autologous hematopoietic stem cell transplantation within 6 months prior to treatment initiation. 13. History of prior allogeneic hematopoietic stem cell transplantation. 14. Major surgery within 4 weeks prior to treatment initiation. 15. History of a non-lymphoma malignancy in the past five years except for the following: adequately treated cervical carcinoma in situ, local basal cell or squamous cell carcinoma of the skin. 16. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the drug or previous significant bowel resection that would preclude adequate absorption of the study drug. 17. History of hypersensitivity to drugs similar to the study drug or inactive excipients of the study drug. 18. Women who are breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area Under the Plasma Concentration Versus Time Curve (AUC) | 1 month |
| Dose Limiting Toxicity (DLT) | 1 month |
| Time to Peak Plasma Concentration（Tmax） | 1 month |
| Peak Plasma Concentration (Cmax) | 1 month |
| Half-life Time(t1/2) | 1 month |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate (ORR) | up to 12 months |
| Lymph Node Response (LNR) | up to 12 months |
| Time to Response (TTR) | up to 12 months |
| Progression-Free Survival (PFS) | up to 12 months |
| Duration of Response (DOR) | up to 12 months |
Countries
China
Contacts
Primary ContactWei Guo
Backup ContactXiaodan Lyu
Outcome results
None listed